Study: Breast cancer drug increases the risk of uterine cancer
Study: Breast cancer drug increases the risk of uterine cancer
NEW YORK (Reuters Health) - Breast cancer, which is used by thousands of women, increases the risk of developing uterine cancer, according to a recent scientific study led by Irish researchers.
According to the site of the newspaper "Daily Mail" British, the Irish study found that taking Tamoxifen for 10 years increases the risk of women with endometrial cancer from 1.5% to 3.5%.
Previous research suggests that tamoxifen inhibits the hormone estrogen from stimulating the growth of breast cancer, which can be given as a treatment or preventive treatment for people with a strong family history of the disease.
Although the drug prevents the hormone estrogen in the breast tissue, it works like the uterine hormone, which increases the risk of endometrial cancer in users.
According to the American Cancer Society, tamoxifen causes endometrial cancer in about one in every 500 women.
The results were published recently in the British Journal of Surgery.Study: Breast cancer drug increases the risk of uterine cancer
NEW YORK (Reuters Health) - Breast cancer, which is used by thousands of women, increases the risk of developing uterine cancer, according to a recent scientific study led by Irish researchers.
According to the site of the newspaper "Daily Mail" British, the Irish study found that taking Tamoxifen for 10 years increases the risk of women with endometrial cancer from 1.5% to 3.5%.
Previous research suggests that tamoxifen inhibits the hormone estrogen from stimulating the growth of breast cancer, which can be given as a treatment or preventive treatment for people with a strong family history of the disease.
Although the drug prevents the hormone estrogen in the breast tissue, it works like the uterine hormone, which increases the risk of endometrial cancer in users.
According to the American Cancer Society, tamoxifen causes endometrial cancer in about one in every 500 women.
The results were published recently in the British Journal of Surgery.Study: Breast cancer drug increases the risk of uterine cancer
NEW YORK (Reuters Health) - Breast cancer, which is used by thousands of women, increases the risk of developing uterine cancer, according to a recent scientific study led by Irish researchers.
According to the site of the newspaper "Daily Mail" British, the Irish study found that taking Tamoxifen for 10 years increases the risk of women with endometrial cancer from 1.5% to 3.5%.
Previous research suggests that tamoxifen inhibits the hormone estrogen from stimulating the growth of breast cancer, which can be given as a treatment or preventive treatment for people with a strong family history of the disease.
Although the drug prevents the hormone estrogen in the breast tissue, it works like the uterine hormone, which increases the risk of endometrial cancer in users.
According to the American Cancer Society, tamoxifen causes endometrial cancer in about one in every 500 women.
The results were published recently in the British Journal of Surgery.Study: Breast cancer drug increases the risk of uterine cancer
NEW YORK (Reuters Health) - Breast cancer, which is used by thousands of women, increases the risk of developing uterine cancer, according to a recent scientific study led by Irish researchers.
According to the site of the newspaper "Daily Mail" British, the Irish study found that taking Tamoxifen for 10 years increases the risk of women with endometrial cancer from 1.5% to 3.5%.
Previous research suggests that tamoxifen inhibits the hormone estrogen from stimulating the growth of breast cancer, which can be given as a treatment or preventive treatment for people with a strong family history of the disease.
Although the drug prevents the hormone estrogen in the breast tissue, it works like the uterine hormone, which increases the risk of endometrial cancer in users.
According to the American Cancer Society, tamoxifen causes endometrial cancer in about one in every 500 women.
The results were published recently in the British Journal of Surgery.Study: Breast cancer drug increases the risk of uterine cancer
NEW YORK (Reuters Health) - Breast cancer, which is used by thousands of women, increases the risk of developing uterine cancer, according to a recent scientific study led by Irish researchers.
According to the site of the newspaper "Daily Mail" British, the Irish study found that taking Tamoxifen for 10 years increases the risk of women with endometrial cancer from 1.5% to 3.5%.
Previous research suggests that tamoxifen inhibits the hormone estrogen from stimulating the growth of breast cancer, which can be given as a treatment or preventive treatment for people with a strong family history of the disease.
Although the drug prevents the hormone estrogen in the breast tissue, it works like the uterine hormone, which increases the risk of endometrial cancer in users.
According to the American Cancer Society, tamoxifen causes endometrial cancer in about one in every 500 women.
The results were published recently in the British Journal of Surgery.Study: Breast cancer drug increases the risk of uterine cancer
NEW YORK (Reuters Health) - Breast cancer, which is used by thousands of women, increases the risk of developing uterine cancer, according to a recent scientific study led by Irish researchers.
According to the site of the newspaper "Daily Mail" British, the Irish study found that taking Tamoxifen for 10 years increases the risk of women with endometrial cancer from 1.5% to 3.5%.
Previous research suggests that tamoxifen inhibits the hormone estrogen from stimulating the growth of breast cancer, which can be given as a treatment or preventive treatment for people with a strong family history of the disease.
Although the drug prevents the hormone estrogen in the breast tissue, it works like the uterine hormone, which increases the risk of endometrial cancer in users.
According to the American Cancer Society, tamoxifen causes endometrial cancer in about one in every 500 women.
The results were published recently in the British Journal of Surgery.
Out Of Topic Show Konversi KodeHide Konversi Kode Show EmoticonHide Emoticon